For personal use only

ASX ANNOUNCEMENT



29 April 2025

Zelira boosts financial flexibility with R&D refund and ATM facility as HOPE® SPV FDA preparations continue

QUARTERLY ACTIVITIES REPORT
FOR Q3 FY2025

Key Highlights

- **$1,153,000 R&D Tax Incentive refund received to support development programs and operations**
  - Provides non-dilutive funding to advance development programs and support operational activities
- **$1 million At-the-Market (ATM) funding facility established for flexible capital access**
  - Provides Zelira with access to cost-effective standby equity capital during its 12-month term
- **Post reporting period, full conversion of US$3.25 million convertible notes into equity in HOPE® 1 SPV**
- **Capsule formulation development for HOPE® and Zenivol® remains on track for mid to late 2025 completion as part of Zyraydi™ delivery platform rollout**

For personal use only

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development and commercialisation of clinically validated cannabinoid-based medicines, is pleased to provide its quarterly activities report and Appendix 4C for the three months ended 31 March 2024 (Q3 FY2025).



Commenting on the operational progress in Q3 FY2025, Global Managing Director & CEO, Dr Oludare Odumosu said:

This quarter marked a steady continuation of our focus on clinical advancement and financial discipline to support the development of our pipeline and operations. We made meaningful progress on preparations for the FDA clinical trial of HOPE® 1, including further engagement with our CRO to finalise the study design in line with prior FDA feedback.

To support these preparations, we further strengthened our balance sheet through the receipt of a $1.15 million R&D Tax Incentive refund and the establishment of a $1 million At-the-Market equity facility, allowing us to access standby capital as needed. Additionally, the successful full conversion of the US$3.25 million of convertible notes into equity within the HOPE® 1 SPV has significantly strengthened the capital structure and removed debt obligations.

Development of the capsule formulation for both HOPE® and Zenivol® using our proprietary Zyraydi™ technology remains on track for completion in mid to late 2025. This project continues to form a core part of our product strategy, aimed at enhancing formulation consistency and positioning both products for broader market readiness. As we move through the second half of the financial year, our focus remains on disciplined execution across our clinical programs and operational priorities.



For personal use only

$1.15 million R&D tax incentive refund

In February, Zelira received $1,153,000 under the Australian Federal Government's R&D Tax Incentive Scheme. These funds will be used for general working capital and to advance clinical development efforts across the product portfolio.

$1 million At-the-Market facility secured

Zelira established a $1 million At-the-Market (ATM) equity facility with Securities Vault Pty Ltd. The ATM offers access to standby equity capital over a 12-month period, giving the company flexibility to align capital raising with operational needs. Zelira retains full control over the placement terms and may terminate the agreement at any time without penalty.

The ATM facility enables capital to be raised with minimal dilution, as there are no attaching options, rights, or other complex instruments commonly associated with traditional placements. As such, it allows the Company to pursue other forms of capital raising in parallel, providing additional financial flexibility.

Full conversion of convertible notes into equity in HOPE® 1 SPV

Post reporting period, Zelira completed the full conversion of USD $3.25 million in Convertible Notes, plus USD $326,876 in accrued interest, into equity within the Zelira-HOPE 1 SPV.

The full conversion strengthens the SPV's capital structure and positions Zelira for the next phase of the institutional capital raise, which will support the ongoing FDA clinical trial program for HOPE® 1, initially targeting the treatment of Autism Spectrum Disorder in patients with Phelan-McDermid Syndrome.

Operational activities

The performance in Q3 FY2025 reflects Zelira's continuous focus on its clinical validation strategy.

Financial snapshot

The Company's net cashflow used in operations for Q3 FY2025 was $739K. Operational expenses mainly comprised:

- Research and development of $389k, up from $292k in Q2 FY2025 reflecting costs associated with the HOPE® 1 trial preparations
- Advertising and marketing of $53k, up from $32k in Q2 FY2025 for Half Year Interim Financial Report release.
- Staff costs of $488k, up from $315k in Q2 FY2025 due to timing of payments
- Administrative and corporate costs of $725k, up from $278k in Q2 FY2025 due to timing of payments
- Variations in costs reflect the timing of payments

For personal use only

Listing Rule 4.7C.3

In item 6 of the attached Appendix 4C, payments to related parties comprised of $257k Director Services, $58k to Non-Director Services and $149k interest under the unsecured loan facility.

As at 31 March 2025, the Company had a cash position of $363k.

Strategy and outlook

Clinical validation and product development remains core to Zelira's growth plans. Zelira is focused on its clinical activities to develop and evaluate the efficacy, safety and tolerability of its proprietary formulations and products.

FDA clinical trials will be an important next step for two key patent-protected products:

- HOPE® 1: Via the establishment of the HOPE® 1 SPV, Zelira has successfully gained the resources to start the FDA clinical trials for HOPE® 1, a patent-protected autism treatment. Zelira has commenced the FDA trial process with appointed CRO iNGENU and has completed the Target Product Profile.
- Diabetic Nerve Drug Treatment ZLT-L-007: Following the receipt of the positive top-line results from the IRB approved diabetic drug trial, demonstrating ZLT-L-007 outperformed Pharma drug Lyrica®, Zelira is evaluating the further progression of ZLT-L-007 into formal FDA clinical trials.



This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

For personal use only

For further information please contact

Company
Dr Oludare Odumosu
Managing Director & CEO
+1 909 855 0675
oodumosu@zeliratx.com

Investors
Rebecca Culbertson
Executive Director, Automic Group
+61 400 955 295
rebecca.culbertson@automicgroup.com.au

Australia
Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
+61 8 6558 0886
Fax: +61 8 6316 3337
enquiries@zeliratx.com
www.zeliratx.com
ACN 103 782 378

USA
5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
+1 484 630 0650

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) Zelira is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic noncancer pain as well as offering over the counter [OTC] products.

Zelira has established a special purpose vehicle (SPV) to conduct FDA Phase 1, Phase 2 and Phase 3 clinical trials for Zelira's proprietary and patent protected HOPE® 1. Zelira has contributed to the SPV its HOPE® 1 product, IP and real-world data for 55% equity ownership of the SPV. Cash investors will contribute a total of circa US$35 million to fund the SPV and US FDA trials for HOPE® 1 in exchange for a cumulative equity interest of 45% of the SPV. Zelira will manage the SPV as part of its business platform. The SPV has appointed iNGENū CRO Pty Ltd (iNGENū) as its Contract Research Organisation (CRO) to lead the clinical validation and regulatory registration of the study product with the US FDA through the submission of an Investigative New Drug (IND) application.

In May 2023, Zelira completed an IRB approved strategically designed multi-arm, head-to-head study targeting diabetic nerve pain. The clinical trial included a comprehensive comparison against the widely recognised and highly successful multi-billion dollar revenue generating drug Lyrica® (Pregabalin). With the findings underscoring the exceptional efficacy of our treatments in managing pain, with ZLT-L-007 demonstrating the most substantial reduction in pain severity, particularly at the 60-day and 90-day follow-up periods. Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi™, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

Zelira's Rx business generates revenue from its proprietary medication, HOPE. The Company has two proprietary formulations under the HOPE® brand that are generating revenue in Australia, Washington, D.C., Pennsylvania and Louisiana. Zelira will also be expanding commercialisation of ZENIVOL® – the world's first clinically validated cannabinoid drug for treatment of chronic insomnia into Germany via its German commercialisation partner Adjupharm GmbH following recent approval from German regulatory authority BfArM. Zelira's OTC products in the oral and dermatology health care sectors are also generating revenue. Zelira, in partnership with SprinJeneCBD, launched a full line of oral care products, currently generating revenue in the US. Zelira also launched in 2021 the RAF FIVE™ brand, which consists of five OTC acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).

For further information, please visit: **zeliratx.com**

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Zelira Therapeutics Limited

ABN	**Quarter ended ("current quarter")**
27 103 782 378	31 MARCH 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	2	19
1.2	Payments for		
	(a) research and development	(389)	(901)
	(b) product manufacturing and operating costs	(3)	(9)
	(c) advertising and marketing	(53)	(125)
	(d) leased assets	(79)	(256)
	(e) staff costs	(488)	(1,303)
	(f) administration and corporate costs	(725)	(1,628)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(157)	(322)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	1,153	1,153
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(739)**	**(3,372)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

For personal use only

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(28)	(28)
3.5	Proceeds from borrowings	-	2,098
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material) – HOPE SPV funding – refer Note 7	1,094	1,094
3.10	**Net cash from / (used in) financing activities**	**1,066**	**3,164**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	38	586
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(739)	(3,372)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,066	3,164
4.5	Effect of movement in exchange rates on cash held	(2)	(15)
4.6	**Cash and cash equivalents at end of period**	**363**	**363**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	354	29
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	9	9
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**363**	**38**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	464
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Director Services

Executive Board Remuneration - $241,000

Non-Executive Board Remuneration - $16,000

Non-Director Services

Accountancy fees - $39,000

Company Secretarial Services - $19,000

Interest on loan $149,000

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	2,098	2,098
7.2	Credit standby arrangements	-	
7.3	Other (please specify) Hope SPV convertible notes	5,175	5,175
7.4	**Total financing facilities**	7,273	7,273

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Loan facilities

Lender:	Mr Osagie Imasogie
Amount:	US$1,400,000
Interest Rate:	20.0% per annum paid monthly
Commencement date	28 June 2024
Maturity	28 June 2026

Hope SPV convertible notes

Issuer:	Zelira-Hope1, LLC - Special Purpose Vehicle
Securities:	Convertible note
Amount:	$3,250,000
Interest Rate:	10.0% paid in cash annually in arrears
Note Term:	12 months each

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(739)
8.2	Cash and cash equivalents at quarter end (item 4.6)	363
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	363

8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.5

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Yes

For personal use only

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: As announced on 31 March 2025, the Company has secured a $1 million At-the-Market Facility (ATM) Agreement with Securities Vault Pty Ltd to support its growth objectives. The ATM facility provides Zelira with up to $1 million of standby equity capital over the next 12 months enabling additional flexibility for the Company to conduct capital raising activities over time, closely aligning capital needs with operational activities.

Furthermore, the Company is continuing to progress it funding efforts its HOPE SPV to close the remaining the balance of the circa US$32 million capital raise to fund HOPE® 1 trials in the USA. Zelira expects to have subsequent rounds of closings this quarter from its continuing fund-raising efforts to support the HOPE® 1 formal FDA clinical program. The SPV funding includes working capital for the Company to enable it to continue its operations and to meet its business objectives.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes, refer above

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....29 April 2025……

Authorised by: .....By the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only